SIC
MYGN icon

SJS Investment Consulting’s Myriad Genetics MYGN Stock Holding History

SJS Investment Consulting’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.84K Buy
673
+657
+4,106% +$2.98K ﹤0.01% 1490
2026
Q1 		$72 Sell
16
-39
-71% -$203 ﹤0.01% 2191
2025
Q4 		$339 Buy
+55
New +$399 ﹤0.01% 1650
2025
Q1 		– Sell
-2
Closed -$28 – 1647
2024
Q4 		$28 Sell
2
-11
-85% -$203 ﹤0.01% 1577
2024
Q3 		$357 Hold
13
– – ﹤0.01% 1414
2024
Q2 		$318 Hold
13
– – ﹤0.01% 1423
2024
Q1 		$278 Buy
13
+4
+44% +$86 ﹤0.01% 1429
2023
Q4 		$173 Sell
9
-2
-18% -$35 ﹤0.01% 1488
2023
Q3 		$177 Sell
11
-4
-27% -$76 ﹤0.01% 1476
2023
Q2 		$348 Buy
15
+1
+7% +$22 ﹤0.01% 1278
2023
Q1 		$326 Buy
14
+3
+27% +$61 ﹤0.01% 1267
2022
Q4 		$160 Buy
11
+4
+57% +$75 ﹤0.01% 1444
2022
Q3 		$0 Buy
+7
New +$161 ﹤0.01% 1361
2022
Q1 		$0 Buy
+1
New +$26 ﹤0.01% 1122

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SJS Investment Consulting's MYGN Position: Q2 2026 in Review

SJS Investment Consulting increased its Myriad Genetics (MYGN) stake by 4,106% in Q2 2026, buying an estimated $2.98K and bringing the position to 673 shares worth $3.84K. The position accounts for ﹤0.01% of the portfolio, ranked #1490.

SJS Investment Consulting first reported a position in MYGN in Q1 2022 and has held it in 14 quarters since. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • SJS Investment Consulting held 673 shares of Myriad Genetics worth $3.84K as of Q2 2026.
  • SJS Investment Consulting bought 657 Myriad Genetics shares in Q2 2026, an estimated $2.98K.
  • Myriad Genetics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1490 holding.
  • SJS Investment Consulting first reported a position in Myriad Genetics in Q1 2022 and has held it in 14 quarters since.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.